Literature DB >> 29317964

Basaloid Squamous Cell Carcinoma of the Lung Associated With Syndrome of Inappropriate Antidiuretic Hormone Secretion.

Ashraf Abugroun1, Fatima Ahmed1, Toni-Denise Espina1, Alvaro Altamirano Ufion1.   

Abstract

Basaloid squamous cell carcinoma (BSQCC) of the lung is a very rare subtype of squamous cell carcinoma (SCC). There have been no reported cases of syndrome of inappropriate anti-diuretic hormone secretion (SIADH) developing concurrently with this tumor. We herein present a case of a 68-year-old female who was diagnosed with lung mass discovered incidentally on preoperative clearance for surgical fixation of right humeral neck fracture. The patient presented to the hospital with nausea, vomiting, diarrhea and fatigue. Sodium level on admission was 115 mmol/L. Further workup confirmed a diagnosis of BSQCC of the lung and SIADH.

Entities:  

Keywords:  Basaloid squamous cell carcinoma; SIADH

Year:  2017        PMID: 29317964      PMCID: PMC5755626          DOI: 10.14740/wjon1065w

Source DB:  PubMed          Journal:  World J Oncol        ISSN: 1920-4531


  20 in total

Review 1.  Molecular pathology and potential therapeutic targets in esophageal basaloid squamous cell carcinoma.

Authors:  Tsuyoshi Saito; Hiroyuki Mitomi; Takashi Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Syndrome of inappropriate antidiuretic hormone secretion in a patient with large cell neuroendocrine carcinoma.

Authors:  Hyung Jung Oh; Mi Jung Lee; Seon Jung Jang; Dong Ho Shin; Shin-Wook Kang
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

3.  The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.

Authors:  William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

4.  Clinical management of SIADH.

Authors:  Peter Gross
Journal:  Ther Adv Endocrinol Metab       Date:  2012-04       Impact factor: 3.565

5.  Oral tolvaptan is safe and effective in chronic hyponatremia.

Authors:  Tomas Berl; Friederike Quittnat-Pelletier; Joseph G Verbalis; Robert W Schrier; Daniel G Bichet; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 10.121

6.  [Adenocarcinoma and basaloid squamous cell carcinoma in the same lung lobe].

Authors:  Takahiro Sawada; Ryusuke Machino; Miyuki Takeji; Katsumi Kitou
Journal:  Kyobu Geka       Date:  2014-03

7.  Multicentric basaloid carcinoma of lung clinically mimicking metastatic carcinoma: a case report.

Authors:  Sharathkumar Bhagavathi; Chung-Ho Chang
Journal:  Int J Surg Pathol       Date:  2008-05-14       Impact factor: 1.271

8.  [Squamous cell bronchogenic carcinoma with syndrome of inappropriate secretion of antidiuretic hormone].

Authors:  Naoya Katsuragi; Y Shiraishi; Y Nakajima; M Kurai; N Takahashi; S Tanaka
Journal:  Kyobu Geka       Date:  2004-08

Review 9.  The syndrome of inappropriate antidiuretic hormone secretion.

Authors:  Peter H Baylis
Journal:  Int J Biochem Cell Biol       Date:  2003-11       Impact factor: 5.085

10.  Severe hyponatremia due to inappropriate secretion of antidiuretic hormone following pleurodesis.

Authors:  Kazuya Higashihara; Yoshiyuki Kimbara; Yohei Suzuki; Eriko Kawate; Hideki Takahashi
Journal:  Intern Med       Date:  2009-06-15       Impact factor: 1.271

View more
  1 in total

1.  CT findings of basaloid squamous cell carcinoma of the lung in 12 patients: A distinct category of squamous cell carcinoma in 2015 WHO classification of lung tumors.

Authors:  Chu Hyun Kim; Yoon Ki Cha; Joungho Han; Jun Ho Kim; Tae Jung Kim; Myung Jin Chung; Jung Hee Lee; Hyun Jung Yoon
Journal:  Medicine (Baltimore)       Date:  2022-05-13       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.